Carolina Aravena1, Tahir Kansu Bozkurt, Fei Yu, Anthony J Aldave. 1. *Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA; and †Departamento de Oftalmología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Abstract
PURPOSE: To report the long-term outcomes of the Boston type I keratoprosthesis (KPro) in the management of limbal stem cell deficiency (LSCD). METHODS: Retrospective review of KPro procedures performed by a single surgeon from May 1, 2004, to January 1, 2015. RESULTS: One hundred seventy-three KPro procedures were performed in 149 eyes, including 68 in 54 eyes with LSCD. Glaucoma (48% vs. 82%, P < 0.0001) and a history of ≥2 keratoplasties (39% vs. 79%, P < 0.0001) were significantly less common in eyes with LSCD. Preoperative corrected distance visual acuity was ≥20/200 in 7% of eyes with LSCD and 9% of eyes without LSCD. A significantly greater percentage of eyes with LSCD had CDVA ≥ 20/200 at each of the first 5 years after surgery. The only postoperative complication more common in eyes with LSCD compared with eyes without was persistent corneal epithelial defect (50% vs. 28%, P = 0.013), although the associated secondary complications sterile corneal necrosis (22% vs. 11%, P = 0.059) and corneal infiltrate (20% vs. 10%, P = 0.08) were twice as common in eyes with LSCD. Despite this, the retention failure rates in eyes with and without LSCD were similar (0.089/eye-yr vs. 0.071/eye-yr; P = 0.53). CONCLUSIONS: Boston type I keratoprosthesis implantation results in a significant improvement in CDVA in the majority of eyes with LSCD through 5 years after surgery, with better visual outcomes than eyes without LSCD. Although several postoperative complications are more common in LSCD, sight-threatening complications such as endophthalmitis and retinal detachment are not. Additionally, there is no difference in the retention failure rate in eyes with and without LSCD, although a larger number of procedures with longer follow-up will be needed to determine retention outcomes more than 5 years after surgery.
PURPOSE: To report the long-term outcomes of the Boston type I keratoprosthesis (KPro) in the management of limbal stem cell deficiency (LSCD). METHODS: Retrospective review of KPro procedures performed by a single surgeon from May 1, 2004, to January 1, 2015. RESULTS: One hundred seventy-three KPro procedures were performed in 149 eyes, including 68 in 54 eyes with LSCD. Glaucoma (48% vs. 82%, P < 0.0001) and a history of ≥2 keratoplasties (39% vs. 79%, P < 0.0001) were significantly less common in eyes with LSCD. Preoperative corrected distance visual acuity was ≥20/200 in 7% of eyes with LSCD and 9% of eyes without LSCD. A significantly greater percentage of eyes with LSCD had CDVA ≥ 20/200 at each of the first 5 years after surgery. The only postoperative complication more common in eyes with LSCD compared with eyes without was persistent corneal epithelial defect (50% vs. 28%, P = 0.013), although the associated secondary complications sterile corneal necrosis (22% vs. 11%, P = 0.059) and corneal infiltrate (20% vs. 10%, P = 0.08) were twice as common in eyes with LSCD. Despite this, the retention failure rates in eyes with and without LSCD were similar (0.089/eye-yr vs. 0.071/eye-yr; P = 0.53). CONCLUSIONS: Boston type I keratoprosthesis implantation results in a significant improvement in CDVA in the majority of eyes with LSCD through 5 years after surgery, with better visual outcomes than eyes without LSCD. Although several postoperative complications are more common in LSCD, sight-threatening complications such as endophthalmitis and retinal detachment are not. Additionally, there is no difference in the retention failure rate in eyes with and without LSCD, although a larger number of procedures with longer follow-up will be needed to determine retention outcomes more than 5 years after surgery.
Authors: Ghasem Yazdanpanah; Kelley J Bohm; Omar M Hassan; Faris I Karas; Abdelrahman M Elhusseiny; Manachai Nonpassopon; Muanploy Niparugs; Elmer Y Tu; Joel Sugar; Mark I Rosenblatt; Maria S Cortina; Ali R Djalilian Journal: Am J Ophthalmol Date: 2019-11-12 Impact factor: 5.258
Authors: Mohsin H Ali; Mark S Dikopf; Anthony G Finder; Ahmad A Aref; Thasarat Vajaranant; Jose de la Cruz; Maria Soledad Cortina Journal: Cornea Date: 2018-05 Impact factor: 2.651
Authors: Miguel González-Andrades; Rosario Mata; María Del Carmen González-Gallardo; Santiago Medialdea; Salvador Arias-Santiago; Juliana Martínez-Atienza; Antonio Ruiz-García; Lorena Pérez-Fajardo; Antonio Lizana-Moreno; Ingrid Garzón; Antonio Campos; Miguel Alaminos; Gloria Carmona; Natividad Cuende Journal: BMJ Open Date: 2017-09-24 Impact factor: 2.692
Authors: Kai B Kang; Faris I Karas; Ruju Rai; Joelle A Hallak; Joann J Kang; Jose de la Cruz; Maria S Cortina Journal: PLoS One Date: 2018-02-06 Impact factor: 3.240